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Background: Evidence about the association between antidepressants and the risk of stroke recurrence was scanty.
This study evaluated the risk of stroke recurrence according to using antidepressants in patients with stroke from a
national representative cohort.
Methods: This cohort study followed 16770 patients aged > =20 years who had an incident stroke from 2000 to 2009
from the National Health Insurance Research Database in Taiwan. Records of each antidepressant prescription were
obtained during follow-up. The types of antidepressants were categorized by Anatomical Therapeutic Chemical
classification system: tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), monoamine
oxidase inhibitors (MAOIs), and other antidepressants. The main outcome was a recurrent stroke during the
follow-up period. The time-dependent Cox proportional hazards model was used in the analyses.
Results: During 63715 person-years of follow-up, we documented 3769 events for stroke recurrence. Antidepressants
use was associated with an increased risk of stroke recurrence (adjusted hazard ratio [HR], 1.42; 95 % confidence interval
[C.I.], 1.24–1.62), especially for ischemic stroke (HR, 1.48; 95 % C.I., 1.28–1.70), but not for hemorrhagic stroke (HR, 1.22;
95 % C.I., 0.86–1.73). The increased risk of stoke recurrence was found for TCAs use only (HR, 1.41; 95 % C.I., 1.14–1.74),
SSRIs use only (HR, 1.31; 95 % C.I.,1.00–1.73),use of other types of antidepressants only(HR, 1.46; 95 % C.I.,1.15–1.84), or
use of multiple types of antidepressants (HR, 1.84; 95 % C.I.,1.04–3.25).
Conclusions: We demonstrated that use of antidepressants was associated with an increased risk of stroke recurrence,
especially in ischemic stroke among Taiwanese. Further studies are warranted to confirm the possible underlying
mechanisms of these findings.Background
Stroke is one of the leading causes of adult disability
and mortality worldwide, resulting in tremendous socio-
economic burden [1, 2]. The recurrence rate of stroke re-
admission within one year was 13 % in Taiwan [3].
Compared with incident stroke events, recurrent events
were likely to have higher mortality rates, greater levels of
disability, and increased costs [4].
Use of antidepressants had positive effect on the man-
agement of stroke patients due to the reduction in inci-
dence rate of post-stroke depression [5] and improvement
in functional recovery [6, 7], but use of antidepressants* Correspondence: klchien@ntu.edu.tw
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creativecommons.org/publicdomain/zero/1.0/also increased side effects [8]. In the cochrane review, the
authors concluded that SSRIs might improve recovery
after stroke, and that there was heterogeneity between
published trials and methodological limitations [9]. Recent
epidemiological studies had shown antidepressants use
was associated with an increased risk of developing stroke
[10]; however, data on stroke recurrence were limited
[11, 12]. Moreover, some studies have indicated depression
was associated with a higher risk of stroke [13], including
recurrent events [11]. The association of fatal stroke in
patients with depression who receiving antidepressants
was even stronger [14]. The role of depression in the
association between antidepressants use and stroke re-
currence remains unclear. We used the National Health
Insurance Research Database in Taiwan to evaluateticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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creased risk of stroke recurrence.
Methods
Data source and study subjects
This cohort study used the Longitudinal Health Insurance
Database (LHID), a sub-dataset of National Health In-
surance (NHI) Research Database containing healthcare
claims between 1996 and 2010 for a cohort of one million
people randomly sampled from beneficiaries of NHI.
The NHI provides coverage to 99 % or more of Taiwanese
population. LHID consists of many data files, including
inpatient records, ambulatory care records, contracted
pharmacies records, and registries for beneficiaries and
contracted medical facilities.
Included in this study were patients had a first
hospitalization with diagnosis of stroke during 2000 and
2009. The date of the first hospitalization for stroke was
identified as the index date. Stroke was identified by prin-
cipal diagnosis with ICD-9-CM code (International Classi-
fication of Diseases, 9th revision, Clinical Modification
codes) 430 to 432 for hemorrhagic stroke and 433 to 437
for ischemic stroke. Those who had any diagnosis of
stroke from 1996 to 1999 were excluded to reduce the
possibility of including prevalent stroke cases. We further
excluded patients who were aged <20 years (N = 91), who
had inappropriate data with index date after the date of
withdrawing from insurance (N = 293), and patients with
recurrent stroke or died within 30 days after index date
(N = 2232). Patients who had use of combinations of
antidepressants and psycholeptics (amitriptyline-psy-
choleptics or melitracen-psycholeptics) (N = 1553) or
too high dose (>3 DDDs, defined daily doses) (N = 69)
during the follow-up period were also excluded. There-
fore, the study included 16770 patients with stroke
(Fig. 1). This study was approved by the institutional
ethics review board at the National Taiwan University
Hospital.
Exposure to antidepressants and covariates
For each patient, the records (detail information of drug
code by Bureau of National Health Insurance, total
dosage and days of use for each prescription) of pre-
scriptions of antidepressants were obtained during the
follow-up. The types of antidepressants were categorized
by Anatomical Therapeutic Chemical (ATC) classification
system [15]: non-selective monoamine reuptake inhibitors
(tricyclic antidepressants, TCAs), selective serotonin
reuptake inhibitors (SSRIs), monoamine oxidase inhib-
itors (MAOIs), and other antidepressants. The average
dosage for the each prescription of antidepressants per
day was calculated. We classified average dose by de-
fined daily doses (DDDs) [15], as defined by the World
Health Organization, into <0.5, 0.5–1, and > =1 DDDs.Other covariates included sex, age, related-disease
and prescriptions of other drugs within one year before
the index date such as antipsychotics (ATC code:
N05A), antithrombotic agents included anticoagulant
(ATC code: B01AA03) and antiplatelet (ATC code:
B01AC06, B01AC04, B01AC05, B01AC23, B01AC07),
anti-inflammatory (ATC code: M01A), antidepressants
use before stroke (ATC code: N06A), depression (ICD-9-
CM code: 296.2, 296.3, 300.4, 311), other mood disorders
or (ICD-9-CM code: 296.0, 296.1, 296.4–296.9) anxiety
(ICD-9-CM code: 300.0), atrial fibrillation (ICD-9-CM
code: 427.3), coronary heart disease (ICD-9-CM code:
410–414), congestive heart failure (ICD-9-CM code: 428),
chronic obstructive pulmonary disease (ICD-9-CM code:
490,491,492,493,494,495,496), cancer (ICD-9-CM code:
140–208), diabetes mellitus or medicine treatment (ICD-
9-CM code: 250; ATC code: A10), hypertension or medi-
cine treatment (ICD-9-CM code: 401–405; ATC code:
C02, C03, C07, C08, C09), and hyperlipidemia or medicine
treatment (ICD-9-CM code: 272; ATC code: C10). These
variables were all possible confounders between antide-
pressants and stroke recurrence. The presence of depres-
sion during the follow-up was also obtained.
Main outcome
The main outcome was a re-hospitalization with
hemorrhagic stroke or ischemic stroke during the
follow-up period. The follow-up started from the index
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the date of stroke recurrence, the date of withdrawing
from insurance, or date of termination of this study,
December 31, 2010; whichever came first.
Statistical analyses
Demographic and clinical characteristics between use of
antidepressants group (at least one prescription of anti-
depressants during follow-up) and non-use were com-
pared by the chi-square test. We also divided the type of
antidepressants into TCAs, SSRIs, MAOIs, others, or
multiple types, as well as dose groups into >0.5, 0.5–1,
and > =1 DDDs to perform the descriptive analyses. Be-
cause of the time-varying nature of drug use, we defined
the duration of antidepressants exposure as days of use
for each prescription from database at ambulatory care,
and contracted pharmacies, but not at inpatient records
because data on days supplied for each prescription were
not obtained. We classified the exposure status into
“use” during the duration of antidepressants and “non-
use” during the days of no prescriptions. We computed
their incidence rate (per 1000 person-year) by dividing
number of events of recurrent stroke with person-years
of exposure to each antidepressant. We used the Simon
and Makuchmethod [16] to graphically represent sur-
vival curves for time to use of antidepressants by Stata
to compute ‘Kaplan-Meier’ estimates for time-dependent
covariates [17].
We used univariable and multivariable models to esti-
mate the hazard ratios (HR) and 95 % confidence inter-
val (C.I.) by the Cox proportional hazards model with
time-varying antidepressants use to assess the associ-
ation between each antidepressants use category and re-
current stroke with “non-use” as the reference group
and adjusted the models for demographic and clinical
characteristics. Moreover, subgroup analyses were per-
formed including antidepressants use before stroke or
not (prevalent users, or new users), depression status
(no-diagnosed depression, prevalent depression, or post-
stroke depression with newly-diagnosed depression),
other drugs use, and other disease. Finally, we performed
two sensitivity analyses. First, the duration of antidepres-
sants exposure was redefined by adding seven days to
the end of days supply for each prescription in order to
take into account for the potential carry over effect and
gaps in therapies [10]. Second, we added the prescrip-
tions of antidepressants in the inpatient settings. Because
the inpatients claims do not contain information on the
days supply for medications, we defined the duration of
antidepressants exposure using the length of hospital
stay. All analyses were carried out with SAS 9.2 and
Stata 10. A two-sided p value < 0.05 was considered sta-
tistically significant.Results
Of the 16770 stroke patients with mean age of 67.3
years, 4695 (28 %) were taking any antidepressant during
follow-up (median, 3.04 years; interquartile range, 1.31–
5.64). Table 1 showed the baseline characteristics of sub-
jects with use of antidepressants compared with those
with non-use of antidepressants. Stroke patients with
use of antidepressants were more female and ischemic
stroke, as well as had a higher prevalence of diabetes
mellitus, hyperlipidemia, chronic obstructive pulmonary
disease, cancer, depression, anti-inflammatory, anti-
thrombotic agents, antipsychotics, and antidepressants
use before stroke. Among4695stroke patients with anti-
depressants use, the most commonly type of antide-
pressants was TCAs use only (n = 1814 [38 %]) and
SSRIs use only (n =661 [14 %]), and MAOIs use only
(n = 95 [2 %]) were less common. In dose groups, the
group of <0.5 DDDs (50 %) was common, and the pro-
portion of the group of 0.5–1 DDDs and •1 DDDs were
21 % and 28 % respectively.
Figure 2 depicted increased risk of recurrent stroke
with antidepressants use. In Cox proportional hazards
model with time-varying antidepressants use for the uni-
variate analyses, use of antidepressants was found to
have a higher risk of stroke recurrence (HR,1.49;95 %
confidence interval [C.I.],1.30–1.70) (Table 2). After con-
trolling for potential confounding variables, use of anti-
depressants also had a significantly increased risk of
stroke recurrence (HR, 1.42; 95 % C.I.,1.24–1.62). A sig-
nificantly increased risk of stroke recurrence was found
with TCAs use only (HR, 1.41; 95 % C.I.,1.14–1.74),
SSRIs use only (HR, 1.31; 95 % C.I.,1.00–1.73), other an-
tidepressants use only (HR, 1.46; 95 % C.I.,1.15–1.84),
and multiple types use (HR, 1.84; 95 % C.I.,1.04–3.25).
We had similar results for the increased risk of recurrent
stroke with antidepressants use in different dose groups
of <0.5 DDDs (HR, 1.40; 95 % C.I.,1.17–1.67), 0.5–1
DDDs (HR, 1.46; 95 % C.I.,1.10–1.94), and 1 DDDs (HR,
1.43; 95 % C.I.,1.11–1.84). Table 3 summarizes the asso-
ciation between subtype of stroke and antidepressants
use category. We found a similar pattern in ischemic
stroke recurrence and a non-significantly increased risk
of hemorrhagic stroke recurrence.
In subgroup analysis (Table 4), recurrent stroke risk esti-
mates were similar among different depression statuses.
The increased risk of recurrent stroke with antidepres-
sants use in prevalent users (HR, 1.23; 95 % C.I.,0.99–
1.53) was lower than in new users (HR, 1.57; 95 %
C.I.,1.32–1.86). The data provided significant differences
(p for interaction = 0.01) in risk between diabetes users
(HR, 1.70; 95 % C.I.,1.41–2.05) and non-diabetes users
(HR, 1.20; 95 % C.I.,0.99–1.45). The data did not show sig-
nificant evidence of differences in risk related to other
drugs use and other disease. In sensitivity analyses, we
Table 1 Characteristics of Study Subjects
Use of Antidepressants Non-use of Antidepressants
(N = 4695, 28 %) (N = 12075, 72 %)
n % n % p-value
Sex (Female) 2046 (43.6) 4806 (39.8) <.001
Age (years)
18–44 240 (5.11) 797 (6.60) <.001
45–54 593 (12.6) 1580 (13.1) <.001
55–64 957 (20.4) 2321 (19.2) <.001
64–74 1536 (32.7) 3399 (28.1) <.001
> = 75 1369 (29.2) 3978 (32.9) <.001
Stroke type
Hemorrhagic stroke 761 (16.2) 2493 (20.6) <.001
Ischemic stroke 3934 (83.8) 9582 (79.4) <.001
Antipsychotics 1515 (32.3) 3338 (27.6) <.001
Antithrombotic agents
anticoagulant 133 (2.83) 395 (3.27) 0.14
antiplatelet 3130 (66.7) 7240 (60.0) <.001
Anti-inflammatory 3970 (84.6) 9354 (77.5) <.001
Antidepressants use before index date 1617 (34.4) 964 (7.98) <.001
Depression 397 (8.46) 176 (1.46) <.001
Anxiety or other mood disordersa 354 (7.54) 449 (3.72) <.001
Atrial fibrillation 302 (6.43) 935 (7.74) 0.004
Coronary heart disease 1065 (22.7) 2534 (21.0) 0.016
Congestive heart failure 317 (6.75) 959 (7.94) 0.009
Chronic obstructive pulmonary disease 804 (17.1) 1912 (15.8) 0.042
Cancer 59 (1.26) 88 (0.73) <.001
Diabetes mellitusϮ 1775 (37.8) 4120 (34.1) <.001
HypertensionϮ 4210 (89.7) 10724 (88.8) 0.11
HyperlipidemiaϮ 1673 (35.6) 3765 (31.2) <.001
aOther mood disorders included manic disorder, bipolar disorder or anxiety
ϮA patient was identified as having these comorbidities if he or she had a ICD-9-CM diagnosis code of that comorbidity on outpatient or inpatient claims, or a





































Fig. 2 Survival Curves of Stroke Recurrence for Antidepressants use
during All Follow-up time Using the Simon and Makuch Method
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nificant with antidepressants use in duration plus 7 days
(HR, 1.33; 95 % C.I.,1.17–1.52) and adding inpatient re-
cords (HR, 1.19; 95 % C.I.,1.05–1.36).
Discussion
This study showed that stroke patients prescribed for
antidepressants had 40 % greater risk of stroke recur-
rence. The association was stronger for ischemic stroke
than for hemorrhagic stroke. The increased risk was ob-
served in association with prescriptions for antidepres-
sants subclass of TCAs, SSRIs, the group of others, and
multiple types. In addition, a higher risk of stroke recur-
rence with antidepressants among diabetic patients was
found.
Table 2 The Risk of Stroke Recurrence in association with Antidepressants
N for Stroke Recurrence/Person-years Rate per 1000 Person-Years Crude HR (95 % CI) Adjusted HRa (95 % CI)
Non-use of Antidepressants 3532/59400 59.5 1 1
Use of Antidepressants 237/2440 97.1 1.49 (1.30, 1.70) 1.42 (1.24, 1.62)
Type of Antidepressants
TCAs only 88/910 96.8 1.48 (1.20, 1.83) 1.41 (1.14, 1.74)
SSRIs only 53/617 86.0 1.38 (1.05, 1.81) 1.31 (1.00, 1.73)
MAOIs only 10/91 110.4 1.45 (0.78, 2.70) 1.41 (0.76, 2.63)
Others only 74/732 101.1 1.53 (1.22, 1.93) 1.46 (1.15, 1.84)
Multiple types 12/91 132.4 1.93 (1.09, 3.40) 1.84 (1.04, 3.25)
Dose Group+
<0.5 DDDs 126/1294 97.4 1.47 (1.23, 1.75) 1.40 (1.17, 1.67)
0.5–1 DDDs 48/492 97.6 1.54 (1.16, 2.05) 1.46 (1.10, 1.94)
> = 1 DDDs 63/654 96.4 1.50 (1.17, 1.92) 1.43 (1.11, 1.84)
HR indicates hazard ratio; 95 % CI: 95 % confidence interval
+Dose Group = The Average Dose of the Prescriptions for Antidepressants per day/Defined Daily Dose; unit: DDDs
aAdjusted for sex, age group, stroke type of the first hospitalization, antipsychotics, antithrombotic agents, anticoagulant, antiplatelet, antidepressant drugs use
before stroke, depression, anxiety or other mood disorders, atrial fibrillation, coronary heart disease, congestive heart failure, COPD, cancer, diabetes mellitus or
medicine treatment, hypertension or medicine treatment, hyperlipidemia or medicine treatment
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ation between antidepressants use and risk of stroke re-
currence. A study in China found an elevated risk of
recurrent stroke after 1-year follow-up in antidepres-
sants users, but the association was statistically non-
significant, partly because of small sample size (RR, 1.96;
95 % C.I.,0.95–4.04) [11]. Another study in Denmark
using propensity score–matching analysis focused on
SSRI use [12]. SSRI exposure was associated with statis-
tically non-significant lower risk of recurrence of ische-
mic stroke (RR, 0.67; 95 % C.I.,0.44–1.02), and non-
significantly higher risk of intracranial bleedings (RR,
1.14; 95 % CI, 0.62–2.12) [12]. The discrepancy in find-
ings among these studies and ours may reflect different
methodology among studies, including differences in pa-
tient populations, reported type of stroke, and methods
of data analysis. We used Cox models with antidepres-
sant exposure as time-dependent covariates to take into
account for switch between classes of antidepressants
and use to non-use. The actual number of days pre-
scribed was the days of exposure in our analysis. How-
ever, all drugs in the Denmark study were included as
time-dependent variables with an assumed average pre-
scription length of 90 days. The extent of drug exposure
in their study might be different from that in ours. A
cochrane review [9] has concluded that SSRIs might im-
prove recovery after stroke. However, different from our
study, the outcomes assessed in the review were neuro-
logical impairment or depression after stroke, but not
stroke recurrence. Furthermore, the authors of the re-
view found high heterogeneity between trials and meth-
odology limitations in these trials. Well-designed trials
are needed before a firm conclusion can be made.The biological mechanisms have been proposed for
the association between antidepressants and stroke.
Antidepressant drugs inhibit the re-uptake receptors or
the activity of metabolic enzymes, thereby increasing the
concentration of serotonin, which induces local vasocon-
striction and increases risk of ischemic stroke [18, 19].
In contrast, evidence also revealed that antidepressants
may inhibit platelet activity and aggregation, thereby
preventing ischemic events [20–22]. This mechanism
also could explain the underlying association between
antidepressants and the increased risk of bleeding. How-
ever, epidemiological studies showed inconclusive results
in the association between antidepressants and risk of
hemorrphagic stroke [23–26]. A study of meta-analysis
reported increased risk of brain hemorrhage associated
with SSRIs [23], whereas other studies, in line with our
analysis, suggested no increased risk [24–26]. Of note,
different from previous studies, our analysis focused on
risk of recurrent stroke. More investigations with stroke
recurrence as the primary end point are required to con-
firm our findings.
Our study showed that the greater risk of stroke recur-
rence with antidepressants in patients with diabetes. Dia-
betes patients with antidepressants had poor adherence
with medication [27], which was associated with adverse
outcomes such as higher glycosylated hemoglobin, sys-
tolic and diastolic blood pressure, and low-density lipo-
protein cholesterol levels [28]. The risk of stroke
recurrence associated with antidepressants use did not
change materially in the analysis stratified by depres-
sion statuses. The indication for antidepressants was
not only for the treatment of mood disorders but also
for patients with various anxiety disorders and off-label
Table 3 The Risk of Recurrence of Ischemic Stroke and Hemorrphagic Stroke in association with Antidepressants
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3012/61194 49.2 1 1 681/68749 9.9 1 1
Use of
Antidepressants
217/2521 86.1 1.58 (1.38, 1.82) 1.48 (1.28, 1.70) 35/3098 11.3 1.10 (0.78, 1.54) 1.22 (0.86, 1.73)
Type of Antidepressants
TCAs only 83/930 945.2 1.64 (1.32, 2.04) 1.53 (1.23, 1.90) 12/1113 10.8 1.03 (0.58, 1.83) 1.08 (0.61, 1.91)
SSRIs only 49/653 649.7 1.46 (1.10, 1.93) 1.34 (1.01, 1.79) 8/794 10.1 1.03 (0.51, 2.06) 1.23 (0.61, 2.48)
MAOIs only 8/93 92.6 1.36 (0.68, 2.72) 1.24 (0.62, 2.49) 2/111 18.0 1.53 (0.38, 6.11) 2.15 (0.54, 8.68)
Others only 11/92 761.1 1.59 (1.24, 2.03) 1.50 (1.17, 1.92) 10/963 10.4 1.01 (0.54, 1.88) 1.12 (0.60, 2.10)
Multiple types 66/756 92.2 2.06 (1.14, 3.73) 1.95 (1.08, 3.54) 3/117 25.7 2.51 (0.81, 7.80) 2.78 (0.89, 8.68)
Dose Group+
<0.5 DDDs 116/1322 87.7 1.58 (1.31, 1.90) 1.49 (1.23, 1.79) 16/1638 9.8 0.93 (0.57, 1.53) 1.00 (0.61, 1.64)
0.5–1 DDDs 46/502 91.7 1.73 (1.29, 2.31) 1.59 (1.19, 2.13) 6/617 9.7 0.97 (0.44, 2.18) 1.11 (0.50, 2.49)
> = 1 DDDs 55/697 78.9 1.48 (1.13, 1.93) 1.37 (1.05, 1.80) 13/844 15.4 1.53 (0.89, 2.66) 1.81 (1.04, 3.16)
HR indicates hazard ratio; 95 % CI: 95 % confidence interval
+Dose Group = The Average Dose of the Prescriptions for Antidepressants per day/Defined Daily Dose; unit: DDDs
aAdjusted for sex, age group, stroke type of the first hospitalization, antipsychotics, antithrombotic agents, anticoagulant, antiplatelet, antidepressant drugs use before stroke, depression, anxiety or other mood












Table 4 The Risk of Stroke Recurrence in association with





Without antipsychotics 1.40 (1.18, 1.66)
With antipsychotics 1.45 (1.16, 1.82)
Without anticoagulant 1.44 (1.25, 1.65)
With anticoagulant 1.24 (0.76, 2.00)
Without antiplatelet 1.41 (1.23, 1.62)
With antiplatelet 1.52 (0.72, 3.22)
Without anti-inflammatory 1.29 (0.90, 1.85)
With anti-inflammatory 1.44 (1.24, 1.67)
Without anxiety or other mood disorders 1.40 (1.07, 1.82)
With anxiety or other mood disorders 1.42 (1.21, 1.66)
Without atrial fibrillation 1.40 (1.22, 1.62)
With atrial fibrillation 1.57 (0.98, 2.50)
Without coronary heart disease 1.36 (1.16, 1.60)
With coronary heart disease 1.59 (1.24, 2.05)
Without congestive heart failure 1.44 (1.25, 1.65)
With congestive heart failure 1.15 (0.68, 1.97)
Without chronic obstructive pulmonary
disease
1.49 (1.29, 1.73)
With chronic obstructive pulmonary disease 1.09 (0.77, 1.54)
Without cancer 1.42 (1.24, 1.63)
With cancer 0.94 (0.26, 3.32)
Without diabetes mellitus 1.20 (0.99, 1.45)
With diabetes mellitus+ 1.70 (1.41, 2.05)
Without hypertension 1.25 (0.69, 2.27)
With hypertension 1.42 (1.24, 1.64)
Without hyperlipidemia 1.41 (1.18, 1.68)
With hyperlipidemia 1.42 (1.15, 1.76)
Antidepressants use before index date
No–New Users 1.57 (1.32, 1.86)
Yes–Prevalent Users 1.23 (0.99, 1.53)
Depression at Baseline (index date) or Post-stroke
No Depression 1.55 (1.32, 1.82)
Depression at Baseline 1.49 (0.99, 2.26)
Post-stroke Depression 1.44 (1.01, 2.07)
HR indicates hazard ratio; 95 % confidence interval
+p-value for the interaction term of diabetes was 0.01, and that of other
variables were all >0.05
aAdjusted for sex, age group, stroke type of the first hospitalization,
antipsychotics, antithrombotic agents, anticoagulant, antiplatelet,
antidepressant drugs use before stroke, depression, anxiety or other mood
disorders, atrial fibrillation, coronary heart disease, congestive heart failure,
COPD, cancer, diabetes mellitus or medicine treatment, hypertension or
medicine treatment, hyperlipidemia or medicine treatment
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the increased risk of recurrent stroke with antidepres-
sants use in prevalent users was lower but non-
significant than in new users, the reduction in the risk
with long-term drug users might happened [30] with
the attrition for susceptible people [31]. We did not ob-
serve dose–response relationship between antidepres-
sants use and stroke recurrence.
The strengths of our study included a large population-
based follow-up study and the integrated details of pre-
scription records such as the drug used, dosages, days of
supply dispensed from database. However, our study had
several potential limitations. First, the history of stroke
prior to 1996 was unknown, but patients with any record
of stroke before 1999 were excluded to reducing misclassi-
fied as an incident case. Second, the validity of diagnosis
of stroke and the recording of prescription in database
may influence our results, even the accuracy of recording
stroke diagnoses and prescriptions in NHIRD was high
[32]. Third, the data of antidepressants use in admission
were excluded due to no information of the duration of
use for each prescription from inpatient records. We used
the length of stay for each admission as an estimate for
duration of antidepressants exposure, and we found the
association weakened but remained statistically significant.
Fourth, we not only lacked for lifestyle information such
as weight, drinking, or smoking status, but also for any
data on stroke location or severity. Fifth, we were un-
able to assess the adherence of the antidepressants be-
cause the information is not available in the claims
database. Poor adherence to antidepressant treatment
may lead to misclassification of exposures resulting in
under-estimation of the drug effect. Sixth, misclassifica-
tion of depression might occur if a patient did not seek
medical care for his or her depressive disorders or if
diagnostic codes were accurate. In our analysis, depression
was treated as a confounder in multivariable analysis.
Misclassification of depression may result in residual
confounding. Finally, we cannot draw conclusions on
causal association from our analysis, as this is an obser-
vational study. This study was national representative
and population-based. The results can be generalizable
to populations in Chinese ethnicity.
Conclusions
We found that use of antidepressants was associated
with an increased risk of stroke recurrence, especially
for ischemic stroke. TCAs, SSRIs, the group of others,
or multiple types users had increased risk of stoke recur-
rence. In addition, a higher risk associated with antidepres-
sants was observed in patients with diabetes. Although
those patients had low dosage of antidepressants, the
closely monitoring the side effects was necessary, particu-
larly for diabetes patients.
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